{"id":44297,"date":"2025-10-24T23:02:39","date_gmt":"2025-10-24T15:02:39","guid":{"rendered":"https:\/\/flcube.com\/?p=44297"},"modified":"2025-10-24T23:02:39","modified_gmt":"2025-10-24T15:02:39","slug":"shanghai-circode-biomed-secures-fda-orphan-designation-for-hm2003-injection-in-thromboangiitis-obliterans","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44297","title":{"rendered":"Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans"},"content":{"rendered":"\n<p>Shanghai CirCode Biomed Co. Ltd. today announced that its proprietary circular\u2011RNA (circRNA) therapeutic <strong>HM2003 Injection<\/strong> has been granted <strong>Orphan Drug Designation (ODD)<\/strong> by the U.S. Food and Drug Administration (FDA) for the treatment of <strong>Thromboangiitis Obliterans (TAO)<\/strong>, also known as Buerger\u2019s disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-thromboangiitis-obliterans\"><strong>What Is Thromboangiitis Obliterans?<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chronic, non\u2011atherosclerotic vasculitis<\/strong> that targets medium and small arteries and veins of the limbs.<\/li>\n\n\n\n<li>Characterized by intense inflammatory cell infiltration, thrombosis, and progressive occlusion of the vascular lumen.<\/li>\n\n\n\n<li>Leads to <strong>Chronic Limb\u2011Threatening Ischemia (CLTI)<\/strong>, especially in young (&lt;\u202f50\u202fyrs) smokers.<\/li>\n\n\n\n<li><strong>No disease\u2011specific therapies<\/strong> currently address the underlying inflammatory and thrombotic pathology, creating a critical unmet medical need.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-hm2003-injection-a-novel-circrna-approach\"><strong>HM2003 Injection \u2013 A Novel circRNA Approach<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug class<\/strong><\/td><td>Circular RNA (circRNA) therapeutic<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Encodes a synthetic peptide that modulates endothelial repair and reduces inflammation; delivered via sub\u2011cutaneous injection.<\/td><\/tr><tr><td><strong>Clinical promise<\/strong><\/td><td>Early\u2011phase data suggest rapid improvement in limb perfusion and reduction in inflammatory biomarkers.<\/td><\/tr><tr><td><strong>Orphan status<\/strong><\/td><td>FDA ODD confers 7\u2011year market exclusivity, tax credits, and potential priority review for subsequent approvals.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance-of-fda-orphan-designation\"><strong>Strategic Significance of FDA Orphan Designation<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated development pathway<\/strong>: Streamlined regulatory review and potential fast\u2011track filing for phase\u202fII\/III studies.<\/li>\n\n\n\n<li><strong>Commercial advantages<\/strong>: Market exclusivity and incentives lower the cost of bringing a therapy to underserved patient populations.<\/li>\n\n\n\n<li><strong>Global impact<\/strong>: Positions Shanghai CirCode as a pioneer in circRNA therapeutics for vascular diseases, opening doors to collaborations with U.S. academic and industry partners.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-next-steps\"><strong>Next Steps<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u202fII clinical trial<\/strong>: Planned enrollment of 120 TAO patients in the U.S. and China to evaluate efficacy and safety.<\/li>\n\n\n\n<li><strong>Regulatory strategy<\/strong>: Submit a Biologics License Application (BLA) in 2027, leveraging the ODD status for priority review.<\/li>\n\n\n\n<li><strong>Commercial planning<\/strong>: Engage with payers and patient advocacy groups to ensure rapid access upon approval.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-statements\"><strong>Forward\u2011Looking Statements<\/strong><\/h2>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai CirCode Biomed Co. Ltd. today announced that its proprietary circular\u2011RNA (circRNA) therapeutic HM2003 Injection&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44298,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1453,24,64],"class_list":["post-44297","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-circode-bio","tag-rare-orphan-disease-drugs","tag-rnai-aso"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai CirCode Biomed Co. Ltd. today announced that its proprietary circular\u2011RNA (circRNA) therapeutic HM2003 Injection has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of Thromboangiitis Obliterans (TAO), also known as Buerger\u2019s disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44297\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans\" \/>\n<meta property=\"og:description\" content=\"Shanghai CirCode Biomed Co. Ltd. today announced that its proprietary circular\u2011RNA (circRNA) therapeutic HM2003 Injection has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of Thromboangiitis Obliterans (TAO), also known as Buerger\u2019s disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44297\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-24T15:02:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2404.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44297#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44297\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans\",\"datePublished\":\"2025-10-24T15:02:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44297\"},\"wordCount\":326,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44297#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2404.webp\",\"keywords\":[\"Circode Bio\",\"Rare \\\/ orphan disease drugs\",\"RNAi \\\/ ASO\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44297#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44297\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44297\",\"name\":\"Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44297#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44297#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2404.webp\",\"datePublished\":\"2025-10-24T15:02:39+00:00\",\"description\":\"Shanghai CirCode Biomed Co. Ltd. today announced that its proprietary circular\u2011RNA (circRNA) therapeutic HM2003 Injection has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of Thromboangiitis Obliterans (TAO), also known as Buerger\u2019s disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44297#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44297\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44297#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2404.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2404.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44297#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai CirCode Biomed Co. Ltd. today announced that its proprietary circular\u2011RNA (circRNA) therapeutic HM2003 Injection has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of Thromboangiitis Obliterans (TAO), also known as Buerger\u2019s disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44297","og_locale":"en_US","og_type":"article","og_title":"Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans","og_description":"Shanghai CirCode Biomed Co. Ltd. today announced that its proprietary circular\u2011RNA (circRNA) therapeutic HM2003 Injection has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of Thromboangiitis Obliterans (TAO), also known as Buerger\u2019s disease.","og_url":"https:\/\/flcube.com\/?p=44297","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-24T15:02:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2404.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44297#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44297"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans","datePublished":"2025-10-24T15:02:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44297"},"wordCount":326,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44297#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2404.webp","keywords":["Circode Bio","Rare \/ orphan disease drugs","RNAi \/ ASO"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44297#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44297","url":"https:\/\/flcube.com\/?p=44297","name":"Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44297#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44297#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2404.webp","datePublished":"2025-10-24T15:02:39+00:00","description":"Shanghai CirCode Biomed Co. Ltd. today announced that its proprietary circular\u2011RNA (circRNA) therapeutic HM2003 Injection has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of Thromboangiitis Obliterans (TAO), also known as Buerger\u2019s disease.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44297#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44297"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44297#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2404.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2404.webp","width":1080,"height":608,"caption":"Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44297#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2404.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44297","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44297"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44297\/revisions"}],"predecessor-version":[{"id":44299,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44297\/revisions\/44299"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44298"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44297"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44297"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44297"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}